Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,^[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.^[2]

Fabre-Kramer Pharmaceuticals

Company type	S Corporation
Industry	Pharmaceuticals
Founded	1992
Headquarters	Houston, Texas
Key people	Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO)
Products	Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD
Website	www.fabrekramer.com

The company has also conducted clinical studies on a gepirone extended release formulation for major depression.^[3][4][5]

In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.^[6]